Transdermal Absorption of Bupranolol in Rabbit Skin in Vitro and in Vivo.
-
- OGISO Taro
- Faculty of Pharmaceutical Sciences, Kinki University
-
- HATA Tomona
- Faculty of Pharmaceutical Sciences, Kinki University
-
- IWAKI Masahiro
- Faculty of Pharmaceutical Sciences, Kinki University
-
- TANINO Tadatoshi
- Faculty of Pharmaceutical Sciences, Kinki University
この論文をさがす
抄録
This study was designed to clarify the percutaneous penetration of bupranolol (BP), a β-adrenoceptor antagonist, through rabbit skin and to compare the in vitro penetration with the in vivo absorption. BP penetrated across the skin slowly in the absence of enhancers in vitro. Isopropyl myristate and N-methyl-2-pyrrolidone enhanced the in vitro penetration, with a 3.6 times higher flux compared with that without enhancers. However, in the in vivo percutaneous absorption, the maximal penetration was obtained with the formulation added d-limonene, with a 3.0 times higher area under the concentration-time curve (AUC) than that for the formulation without enhancers. The plasma levels of BP determined, however, were extremely lower than the theoretical plasma steady-state concentrations predicted. The plasma levels of BP after application of these formulations were maintained in the range of 7—22 ng/ml for 30 h, of which concentrations were above the therapeutically effective concentration (1.5—4 ng/ml). Therefore, the transdermal systems will offer an efficient drug delivery system for the treatment of angina pectoris and tachycardia.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 24 (5), 588-591, 2001
公益社団法人 日本薬学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282679603272704
-
- NII論文ID
- 110003638520
-
- NII書誌ID
- AA10885497
-
- COI
- 1:CAS:528:DC%2BD3MXjt1altL4%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 5765326
-
- PubMed
- 11379788
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可